Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

662
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
662
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

935
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
935
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.3K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

189
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
189
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.1K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Actively targeted dendrimer-metal organic framework drug delivery nanoplatform for the treatment of neuroblastoma.

RSC advances·2026
Same author

Design and optimization of a Cu-MOF@graphene oxide nanozyme for point-of-care colorimetric determination of sarcosine and H<sub>2</sub>O<sub>2</sub>.

RSC advances·2026
Same author

Fortified Long-acting Ocular Gel Laden with Nanoformulated Dexamethasone for Dry Eye Therapy.

AAPS PharmSciTech·2026
Same authorSame journal

Perindopril: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
Same author

Folate-functionalized core-shell nanocarrier System for sustained and targeted delivery of <i>Saraca Indica</i> for breast cancer treatment.

Drug development and industrial pharmacy·2026
Same author

Folic acid-conjugated chitosan/sodium hyaluronate-based hybrid nanocarriers as a dual-targeted delivery system for efficient breast cancer therapy.

International journal of biological macromolecules·2025
Same journal

Preface.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Rosuvastatin calcium: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Kinetic exclusion assay technology: Theory, experimental aspects, and applications in concentration measurements across diverse fields.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Drugs and polymer based local delivery systems in the treatment of periodontal diseases.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Ferulic acid: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
See all related articles

Related Experiment Video

Updated: Sep 27, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Ticagrelor.

Mohamed Fawzy Kabil1, Ahmed S Abo Dena2, Ibrahim M El-Sherbiny1

  • 1Nanomedicine Lab, Center for Materials Science, Zewail City of Science and Technology, 6(th) of October City, Giza, Egypt.

Profiles of Drug Substances, Excipients, and Related Methodology
|April 9, 2022
PubMed
Summary
This summary is machine-generated.

Ticagrelor, a non-thienopyridine antiplatelet agent, inhibits platelet aggregation by blocking P2Y12 receptors. This review covers its properties, uses in acute coronary syndrome, and analytical methods.

Keywords:
AntiplateletBrilintaBriliqueCyclopentyl triazolopyrimidineTicagrelor

More Related Videos

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Related Experiment Videos

Last Updated: Sep 27, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.0K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry

Background:

  • Ticagrelor is a modern antiplatelet medication.
  • It functions by inhibiting the P2Y12 adenosine diphosphate receptor.
  • Approved by the FDA in 2011, it's a non-thienopyridine drug.

Purpose of the Study:

  • To provide a comprehensive overview of ticagrelor.
  • To discuss its physical, chemical, and pharmacokinetic properties.
  • To summarize synthesis, assay methods, and characterization techniques.

Main Methods:

  • Literature review of ticagrelor's properties and applications.
  • Summary of reported analytical and synthesis methodologies.
  • Discussion of pharmacokinetic and pharmacodynamic data.

Main Results:

  • Ticagrelor effectively prevents thromboembolism in acute coronary syndrome patients.
  • Various analytical methods exist for ticagrelor quantification.
  • Established synthesis routes and characterization techniques are available.

Conclusions:

  • Ticagrelor is a significant therapeutic agent for cardiovascular conditions.
  • Understanding its properties and analysis is crucial for clinical application.
  • This review aids analysts in selecting appropriate assay methods.